Madrigal Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2004
Net Income	-444.28	-373.63	-295.35	-241.85	-202.24	-83.95	Upgrade
Depreciation & Amortization	0.57	0.53	0.47	0.41	0.47	0.11	Upgrade
Share-Based Compensation	58.39	49.74	31.63	26.87	20.73	22.76	Upgrade
Other Operating Activities	-4	-0.86	38.4	30.65	23.48	19.45	Upgrade
Operating Cash Flow	-389.32	-324.23	-224.86	-183.92	-157.56	-41.62	Upgrade
Capital Expenditures	-1.8	-1.48	-0.22	-0.21	-0.33	-0.17	Upgrade
Change in Investments	-215.8	-501.04	206.9	-4.85	160.11	30.88	Upgrade
Investing Cash Flow	-217.6	-502.52	206.69	-5.06	159.78	30.71	Upgrade
Share Issuance / Repurchase	1,086	530.48	264.34	171.24	5.09	0.24	Upgrade
Debt Issued / Paid	29.85	64.64	49.11	0	0	0	Upgrade
Financing Cash Flow	1,116	595.12	313.45	171.24	5.09	0.24	Upgrade
Net Cash Flow	509.21	-231.63	295.28	-17.74	7.31	-10.68	Upgrade
Free Cash Flow	-391.12	-325.71	-225.07	-184.13	-157.9	-41.8	Upgrade
Free Cash Flow Per Share	-19.55	-17.43	-13.13	-11.13	-10.22	-2.71	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).